Lab and animal studies suggest CBD may reduce neurodegeneration in Alzheimer's models, but no controlled human trials have been published.
Families exploring Alzheimer's treatment options, researchers planning clinical trials, and clinicians fielding patient questions about CBD.
Zero randomized controlled trials of CBD in Alzheimer's despite promising preclinical data
What the researchers found
Preclinical studies show CBD can mitigate cognitive decline and amyloid-beta-induced neurodegeneration through modulation of oxidative stress and neuroinflammation. CBD also promotes neuroplasticity in the hippocampus. However, no randomized placebo-controlled trials in human Alzheimer's patients exist.
Why it matters
Alzheimer's affects at least 50 million people worldwide with limited treatment options. The gap between promising preclinical CBD data and the absence of rigorous human trials highlights both opportunity and caution.
The numbers in context
At least 50 million people affected by Alzheimer's worldwide. Current treatments limited to cholinesterase inhibitors and memantine. Zero randomized placebo-controlled trials of CBD in Alzheimer's published.
How the study worked
Narrative review examining preclinical and in vitro evidence for CBD in Alzheimer's disease models, as well as the limited available clinical data.
What this study cannot tell us
Narrative review without systematic search. Preclinical findings frequently fail to translate. Available clinical evidence described as conflicting. No RCTs exist.
How to read the evidence
Narrative review relying almost entirely on preclinical data with no human RCTs available.
When this study was published
Published in 2024.
The bigger picture
CBD's anti-inflammatory and neuroprotective properties make it a plausible candidate for Alzheimer's research, but the leap from cell cultures to human clinical benefit is famously unreliable in neurodegenerative disease.
Questions still open
- Why have no randomized controlled trials of CBD in Alzheimer's been conducted despite promising preclinical data?
- Could CBD be more effective as a preventive measure earlier in the neurodegenerative process?
Common questions
Can CBD help with Alzheimer's?
Should Alzheimer's patients take CBD?
Read the original research
Cannabidiol and Alzheimer's disease.
International review of neurobiology, 177, 121-134
Citation
Marques, Bruno L; Campos, Alline C. (2024). Cannabidiol and Alzheimer's disease.. International review of neurobiology, 177, 121-134. https://doi.org/10.1016/bs.irn.2024.04.014
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk